Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17985760 | 0.88 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21011320 | 0.84 | MEN1 (0.43) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL22400069 | 0.84 | MEN1 (0.43) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL14367895 | 0.83 | MEN1 (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL28843387 | 0.82 | MEN1 (0.38) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL11531988 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL12664131 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21774708 | 0.81 | CYP1A2 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL19891843 | 0.81 | MEN1 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL18868116 | 0.81 | MEN1 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797796-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Mabplex International, Ltd. (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-8404465-B2 | Biological synthesis of 6-aminocaproic acid from carbohydrate feedstocks | CELEXION, LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404465-B2 | Biological synthesis of 6-aminocaproic acid from carbohydrate feedstocks | CELEXION, LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | STRACHER ALFRED | 2008-02-14 | — | — | US | disclosed |
| EP-1805207-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | Ceptor Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037133-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | CEPTOR CORPORATION (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | CPT1B, CAPNS1, CAPN1 | MEN1 4472/4885CYP1A2 4395/4885KMT2A 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.